Hidradenitis Suppurativa, Eruptive Melanocytic Nevi, and Keratosis Pilaris–like Eruption in a Patient Treated With Vemurafenib

Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma

“…Localized folliculitis was present in 5 vemurafenib-treated patients (13.9%) and in 8 dabrafenib-treated patients (6.7%). Keratosis pilaris has also been reported to occur in patients treated with vemurafenib 11,12 and occurred in 5 vemurafenib-treated patients (5.6%) and 2 dabrafenib-treated patients (1.7% Changes in melanocytic nevi such as hyperpigmentation, regression, and new primary melanomas were also noted. Three dabrafenib-treated patients (2.5%) developed new primary melanomas, and patients receiving both single-agent BRAF inhibitors had changes in nevi size and color.…”

The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation

“…Median PFS was 5.3 months in the vemurafenib group and 1.6 months in the dacarbazine group. At 6 months, OS was 84 percent (95% confidence interval [CI], 78-89) in the vemurafenib group and 64 percent (95% CI, [56][57][58][59][60][61][62][63][64][65][66][67][68][69][70][71][72][73] in the dacarbazine group. In the interim analysis for OS and the final analysis for PFS, vemurafenib was associated with a relative reduction of 63 percent in the risk of death and of 74 percent in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).…”

“…Less common skin reactions include exfoliative exanthema, 52 panniculitis, 56-61 erythema nodosum (appearing 15 days after initiation of therapy), 57 severe hydradenitis of the scalp and eruptive melanocytic nevi. 32,62 From an Australian perspective, the impact of vemurafenib AEs such as photosensitivity will be greater in those places with high UVA radiation, increasing the risk of significant photosensitivity even over short periods of time. As expected photosensitivity is more likely to occur in summer, and significant exposure may even occur near windows indoors or through car windows.…”

Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients

“…6 In addition to these toxicities, investigators have reported changes in existing melanocytic nevi and development of new primary melanomas and atypical nevi in the setting of therapeutic BRAF inhibition. [7][8][9][10][11][12][13][14][15][16][17][18] Studies have classified excised lesions as common nevi, dysplastic nevi, and melanoma but have not examined these lesions for distinctive histologic features. [9][10][11]17 Although BRAF inhibition has been reported to produce side effects through the paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway in both keratinocytic and melanocytic lesions, 1 the profile of immune response in these lesions has not been previously investigated to our knowledge.…”

“…,11 Eruptive nevi,12,14 new nevi, and new primary melanomas can develop 10,15. Rates of new primary melanoma in trials of dabrafenib and vemurafenib for metastatic melanoma were 3 of 187 (1.6%) patients and 8 of 337 (2.3%) patients, respectively.…”